Antibodies as Drugs: B Cell Biology 20B1

Web Desc
Antibodies as Drugs: From B Cell Biology to New Treatments Organizer(s): Paul Carter, Janine Schuurman and Karl Dane Wittrup Date: February 02 - 06, 2020 Location: Eldorado Hotel & Spa, Santa Fe, NM, USA Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology Supported by a grant from Genentech For important information on the coronavirus, please click here Summary of Meeting: Since the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients. Scholarship Deadline: October 17 2019 Discounted Abstract Deadline: October 17 2019 Abstract Deadline: November 5 2019 Discounted Registration Deadline: December 5 2019 Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested. Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting: We gratefully acknowledge additional support from these exhibitors at this conference: We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: Adimab, Inc. Akrevia Therapeutics Genentech, Inc. Genmab A/S Immatics Biotechnologies GmbH Light Chain Bioscience Regeneron Pharmaceuticals, Inc. We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Antibodies as Drugs: From B Cell Biology to New Treatments

Organizer(s): Paul Carter, Janine Schuurman and Karl Dane Wittrup

Date: February 02 - 06, 2020
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA

Sponsored by BioLegend, Inc., Compass Therapeutics, Incyte Corporation, MorphoSys AG and Surface Oncology

Supported by a grant from Genentech

For important information on the coronavirus, please click here

Summary of Meeting:

Since the mid-1990s, antibodies have grown steadily into a clinically important pharmaceutical class with over 70 antibody-based drugs approved, predominantly in oncology, autoimmunity and inflammation. As the antibody drug field has expanded and matured in recent years, the field has moved from empirical strategies to deep knowledge-based, designer approaches for which understanding of mechanisms of action is critical; there has also been a trend toward increasingly specialized meetings with a narrow focus such as cancer immunotherapy, bispecifics or B cell biology. In contrast, we are proposing a scientifically diverse program that spans a broad range of different and cutting-edge topics relevant to antibody drug development, including antibodies for infectious disease and antibody pharmacology, topics which are often under-represented at major antibody conferences. Additionally, we have chosen a diverse collection of speakers from junior investigators to seasoned researchers from a wide range of institutions in at least eight different countries. We hope and expect that this approach will stimulate ‘cross-pollination’ between disciplines that span the gamut from basic to translational to clinical sciences with the common theme of antibody drugs for the benefit of patients.

Scholarship Deadline: October 17 2019

Discounted Abstract Deadline: October 17 2019

Abstract Deadline: November 5 2019

Discounted Registration Deadline: December 5 2019

Abstract submission is now closed. Registered attendees may bring a poster onsite. Please contact our office at +1 800-253-0685; +1 970-262-1230 or email info@keystonesymposia.org if you are interested.

Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:

We gratefully acknowledge additional support from these exhibitors at this conference:

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Adimab, Inc.

Akrevia Therapeutics

Genentech, Inc.

Genmab A/S

Immatics Biotechnologies GmbH

Light Chain Bioscience

Regeneron Pharmaceuticals, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found